Aker BioMarine

Earnings Release • Feb 15, 2023

Aker BioMarine ASA - results fourth quarter 2022

Aker BioMarine ASA - results fourth quarter 2022

15 February 2023: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 79 million and Adjusted EBITDA of USD 21 million for the fourth quarter 2022.

Highlights fourth quarter:

- Revenues of USD 79 million in Q4 2022, up 4% from same quarter last year

- Adjusted EBITDA of USD 21 million in Q4 2022, up from USD 7 million the same quarter last year

- In the quarter, the company initiated an improvement program to streamline operations, improve margins and cut cost. The implementation of such measures started early 2023

- Offshore production volume was 1,960 MT in the quarter and total volume for the full year was 52,000 MT, 19% higher than in 2021

“Aker BioMarine delivered 6% revenue growth in 2022 with an adjusted EBITDA margin of 25%, up from 18% in 2021. In the year, we improved our krill harvesting and progressed both our ingredients and Brands business. To further strengthen our core business and create a more robust company, we have initiated an improvement program, where our goal is to realize annualized effects in excess of USD 20 million within the next two years”, said Matts Johansen, CEO of Aker BioMarine.

At 09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.

A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address.

For further information, please contact

Carl Christian Bachke, Investor Relations

Mobile: +47 909 808 48

Email: carl.bachke@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Aker BioMarine

Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.